Background: Hereditary angioedema (HAE) with normal C1-INH (HAEnCI) may be
sequencing of the whole exome combined with family studies.
Hereby we found a mutation in the plasminogen (PLG) gene, which was previously unknown to be disease-causing and cosegregated with clinical symptoms in patients as an autosomal dominant trait.
These findings suggest a novel type of HAE characterized by normal C1-INH function and level, absence of a specific F12 gene mutation, and presence of the novel PLG gene mutation (HAE-PLG).
| ME TH ODS
The study comprises analysis of whole-exome sequencing (WES), Sanger sequencing, and clinical and biochemical data of patients.
| Probands
Probands included patients, symptom-free family members, and healthy controls. Study patients with HAE were selected by the following criteria: (i) Patients had recurrent swellings of skin, abdominal pain attacks, tongue swellings, or laryngeal attacks in the absence of urticaria; (ii) patients had normal C1-INH function and concentration in plasma; (iii) patients had no HAE-specific F12 gene mutations comprising the missense mutations p.Thr328Lys and p.Thr328Arg, the large deletion c.971_1018 + 24del 72, and the duplication c.892_909dup; (iv) patients came from families with 2 or more symptomatic patients with HAE; and (v) within the families, the patients came from two or more generations. All patients were surveyed in the Angioedema Outpatient Service at the Johannes Gutenberg University, Mainz, Germany (AOS).
Twenty-two subjects (20 patients and two healthy persons) were investigated by WES and Sanger sequencing (sample A). Additionally, 13 relatives of 4 families and 38 index patients of 38 unrelated families (sample B) were examined by Sanger sequencing.
One hundred and five healthy individuals (210 alleles), comprising 53 males and 52 females, were sequenced for the presence of the novel PLG gene mutation as controls.
| Collection of clinical data
Clinical data were collected from the patients' medical history and from clinical examinations as well as follow-up records. The study was conducted in the AOS. All subjects analyzed in this study gave written informed consent prior to participation. The local ethics committee approved the study.
| Whole-exome sequencing
EDTA blood was collected from all study participants. All samples were stored at -80°C. DNA was extracted from whole blood according to standard protocols (Qiagen, Hilden, Germany). Exome sequencing was performed as previously described. 7 Briefly, read alignment was performed with BWA (v. 0.5.8) and the human genome assembly hg19 (GRCh37) was used as reference. Single nucleotide variants and small insertions and deletions (indels) were detected using SAMtools (v 0.1.7) using default parameters. According to the pedigrees in Figure 1 , there were a total of 32 patients with clinical symptoms of HAE-PLG. Twenty-five (78%) of them were females and 7 (22%) males. The gender-specific rate of females to males is 3.6-1 in those 4 families. In family D, all identified patients were females.
| Haplotype analysis: common founder effect
In 
| PLG gene mutation in further families (sample B)
To cross-validate the results found in the 7 families analyzed by WES and Sanger sequencing, we determined the presence of the described PLG gene mutation in 38 index patients of 38 different families with HAEnCI without HAE-specific F12 gene mutations using Sanger sequence analysis. The PLG gene mutation was found in 9/38 index patients (37.5%). Summing up over samples A and B, the mutation was found in 27 symptomatic patients and 2 asymptomatic individuals coming from 13/45 (28.9%) families. The PLG gene mutation K330E was not present in the 105 control subjects (210 independent chromosomes).
| Prediction scores
The variant is predicted to be benign and tolerated based on SIFT, 9 CADD, 10 PolyPhen-2, 11 and MutationTaster. 12 
| Clinical symptoms
Clinical data could be obtained from 60 symptomatic patients coming from 13 families with the reported PLG gene mutation and are summarized in Table 1 . 
| Estrogen impact
In 6/43 (14%) women, the first clinical symptoms started after beginning with oral contraceptives. Thirty-one women with HAE-PLG had a total of 73 pregnancies. An onset or worsening of disease during pregnancy was not reported. 
| Treatment

to 43.4 mg/dL). Plasminogen activities in three
women were 131%, 96%, and 70% (reference range: 70%-130%).
| DISCUSSION
Hereditary angioedema with normal C1-INH was first described in 2000. 16, 17 In approximately 30% of patients, it is associated with mutations in the F12 gene (HAE-FXII). 3, 5, 6 Here, we report that
HAEnCI can be associated also with a mutation in the PLG gene. We identified a genetic variant in the PLG gene in patients with HAEnCI.
By whole-exome analysis the mutation was found in four families and by Sanger sequencing in further members of those families as well as HAE-PLG, hereditary angioedema (HAE) with normal C1 inhibitor and mutation in the plasminogen gene; HAE-FXII, HAE with normal C1-INH with HAE-specific mutation in the F12 gene. *All tests on the per-patient and per-attack basis. **Numbers of patients do not add up to 100% because most patients had swellings at various body sites during the course of disease.
ing for HAE-PLG despite benign in silico prediction. Our findings indicate a novel type of HAEnCI which is linked to the described mutation in the PLG gene. The HAE type is termed HAE with normal C1-INH and a mutation in the PLG gene (HAE-PLG).
The mutation reported here leads to an amino acid substitution of lysin by glutamic acid in position 330 located in the kringle 3 domain in PLG. The kringle domains facilitate PLG binding to large surfaces, for example, fibrin, bacterial proteins, cell surfaces, and small-molecule ligands, and have a high influence on the arrangement and function of PLG protein. 18, 19 Functional mutations in the PLG gene may lead to the phenotype of PLG deficiency (PLGD). PLG deficiency has been classified as hypoplasminogenemia or "true" PLGD type I and as dysplasminogenemia or PLGD type II. 20 Hypoplasminogenemia is autosomal recessive inherited and is associated with ligneous lesions on mucous membranes, most commonly ligneous conjunctivitis. Dysplasminogenemia has a normal or slightly reduced antigen and a strongly reduced PLG activity. In dysplasminogenemia, no specific clinical manifestation was reported. 21 Angioedema was not mentioned in patients with PLGD type I or II. Here, we describe a mutation in the PLG gene, which is linked to a novel phenotype. The normal PLG activity reported here in 3 symptomatic patients with HAE-PLG seems to indicate that the PLG gene mutation has no influence on the PLG activity in blood plasma.
Plasminogen is a circulating zymogen that is converted to the In 2006, we identified two missense mutations, T328K, T328R, and later the deletion c.971_1018 + 24del72 in the F12 gene, all coding for the proline-rich region of FXII protein. 3, 29 Recently, it was reported that the three mutant FXII proteins had new sites sensitive to enzymatic cleavage by plasmin. 30 The atypical cleavage of the mutant FXII by plasmin could lead to an increased rate of FXIIa formation, kallikrein-kinin system (KKS) activation, and bradykinin production that is not properly controlled by C1-INH.
In contrast to HAE-FXII, in HAE-PLG the sensitivity of FXII for plasmin can be expected to be normal. In HAE-PLG, the PLG is changed because of one mutation in the kringle 3 domain. The gene mutation might lead to a structural change of the molecule that potentially modifies the function of the mutant PLG. It may show a higher affinity for surfaces and/or may be more accessible for activators such as tPA and uPA. The consequence might be an increased activation of the fibrinolytic system with subsequent formation of plasmin, activation of KKS, and increased production of bradykinin.
Furthermore, we could speculate that the amino acid substitution (K330E) could lead to introduction of a new site in FXII protein leading to enhanced FXII activation, with consequences as described for HAE-FXII. 30 As reported here, the bradykinin-2 receptor antagonist was effective in a high number of attacks in two patients with HAE-PLG.
This provides evidence that bradykinin is produced in acute attacks and may be the main mediator of edema in HAE-PLG. 
ADDENDUM
After submission of our manuscript, an abstract was published reporting a series of 29 unrelated patients with idiopathic angioedema or HAE-unknown. Two patients showed the PLG mutation reported here. 32 Furthermore, an Italian family with HAE and a mutation in the angiopoietin gene was reported. 33 
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